We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder


Department of Health written question – answered on 27th February 2017.

Alert me about debates like this

Photo of Mary Glindon Mary Glindon Shadow Minister (Environment, Food and Rural Affairs) (Farming and Rural Communities)

To ask the Secretary of State for Health, for what reasons a decision has not yet been taken on whether Selective Internal Radiation Therapy should be routinely funded on the NHS following the Commissioning through Evaluation assessment period.

Photo of David Mowat David Mowat The Parliamentary Under-Secretary of State for Health

In order for NHS England to consider whether Selective Internal Radiation Therapy (SIRT) should be routinely commissioned, the clinical data collected by each participating centre must be analysed to establish whether, in the absence of clinical trial evidence, there is sufficient evidence of patient benefit. This part of the Commissioning through Evaluation (CtE) process is led by the National Institute for Health and Care Excellence (NICE).

The analysis phase varies in length, depending on the evaluation measures agreed by clinicians and patients at the start of each scheme. For example, it may be important to test whether the expected benefits of a treatment have been both achieved, and maintained, at 12 and 24 months; or there may be a need to evaluate whether a treatment, such as a novel cancer treatment, has halted the disease process, or improved overall survival, at three and six months.

The evaluation report of the SIRT focussed CtE programme will be submitted to NHS England by NICE and, should the results recommend, a review of the current clinical commissioning policy position will take place. Given the length of the outcome measures in the study, an interim evaluation report is expected to be available in autumn 2017. It is important to note that the national CtE programme operates alongside NHS England’s clinical commissioning policy development process, which remains open to the consideration of new material and published evidence on clinical and/or cost effectiveness at any time.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.